New targets and delivery systems for antifungal therapy

References

• Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents. Adv Pharmacol 1998; 44: 343–500.
   Google Scholar
• Loftsson T, Brewster ME. Pharmaceutical applications of cy-clodextrins. 1. Drug solubilization and stabilization. J Pharm Sci 1996; 85: 1017–1025.
   PubMed Web of Science ®Google Scholar
• Thompson DO. Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals. Crit Rev Ther Drug Carrier Syst 1997; 14: 1–104.
   PubMedGoogle Scholar
• Stella VJ, Rajewski RA. Cyclodextrins: their future in drug formulation and delivery. Pharm Res 1997; 14: 556–567.
   PubMed Web of Science ®Google Scholar
• Stevens DA. Itraconazole in cyclodextrin solution. Pharma-cotherapy 1999; 19: 603–611.
   PubMed Web of Science ®Google Scholar
• Irie T, Uekama K. Pharmaceutical applications of cyclodex-trins. III. Toxicological issues and safety evaluation. J Pharm Sci 1997; 86: 147–162.
   PubMed Web of Science ®Google Scholar
• Barone JA, Moskovitz BL, Guamieri J, et al. Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodex-trin solution versus capsules in healthy volunteers. Agents Chemother 1998; 42: 1862–1865.
   PubMed Web of Science ®Google Scholar
• Van de Velde VJ, Van Peer AP, Heykants JJ, et al. Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cy-clodextrin formulation of itraconazole. Pharmacotherapy 1996; 16: 424–428.
   PubMed Web of Science ®Google Scholar
• Papahadjopoulos D, Vail WJ, Jacobson K, Poste G. Cochleate lipid cylinders: formation by fusion of unilamellar lipid vesicles. Biochim Biophys Acta 1975; 394: 483–491.
   PubMed Web of Science ®Google Scholar
• Zorn L, Jin T, Scolpino A, Mannino RJ. Are cochleates the new lipid-based carrier for oral drug delivery? Abstracts of the 39th International Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 26–29, 1999. Washington DC: American Society for Microbiology, 1999: Abstract 1939.
   Google Scholar
• Graybill JR, Najvar LK, Bocanegra R, Scolpino A, Mannino RJ, Zorn L. Cochleate: A new lipid vehicle for amphotericin B. Abstracts of the 39th International Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 26–29, 1999. Washington DC: American Society for Microbiology, 1999: Abstract 2009.
   Google Scholar
• Seagram I, Jin T, Hyra DA, Mannino RJ, Zarif L. Oral administration of amphotericin B with a new AmB-cochleate formulation: tissue distribution after single and multiple oral dosing. Abstracts of the 39th International Conference on An-timicrobial Agents and Chemotherapy, San Francisco, CA, Sep-tember 26–29, 1999. Washington DC: American Society for Microbiology, 1999: Abstract 1940.
   Google Scholar
• Kreuter J. Nanoparticles and microparticles for drug and vac-cine delivery. J Anat 1996; 189: 503–505.
   PubMed Web of Science ®Google Scholar
• Davis SS. Biomedical applications of nanotechnology - impli-cations for drug targeting and gene therapy. Trends Biotechnol 1997; 15: 217–224. a0 2000 ISHAM, Medical Mycology, 38, Suppl. I, 335-347
   PubMed Web of Science ®Google Scholar
• Hossain MA, Maesaki S, Kakeya H, et al. Efficacy of NS-718, a novel lipid nanosphere-encapsulated amphotericin B, against Cryptococcus neoformans. Antimicrob Agents Chemother 1998; 42: 1722-1725.
   Google Scholar
• Maesaki S, Miyazaki Y, Higashiyama Y, Tomono K, Kohno S. The efficacy and attenuation of nephrotoxicity of NS-718, a novel lipid nanosphere encapsulated amphotericin B against Cryptococcus neoformans infection. Abstracts of the 39th Inter-national Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 26–29, 1999. Washington DC: American Society for Microbiology, 1999: Abstract 2013.
   Google Scholar
• Otsubo T, Maesaki S, Hossain MA, et al. In vitro and in vivo activities of NS-718, a new lipid nanosphere incorporating amphotericin B, against Aspergillus fumigatus. Antimicrob Agents Chemother 1999; 43: 471–475.
   PubMed Web of Science ®Google Scholar
• Kwon GS. Diblock copolymer nanoparticles for drug delivery. Grit Rev Ther Drug Carrier Syst 1998; 15: 481–512.
   PubMed Web of Science ®Google Scholar
• Yu BG, Okano T, Kataoka K, Kwon G. Polymeric micelles for drug delivery: solubilization and haemolytic activity of ampho-tericin B. J Controlled Release 1998; 53: 131–136.
   PubMed Web of Science ®Google Scholar
• Yu BG, Okano T, Kataoka K, Sardari S, Kwon GS. In vitro dissociation of antifungal efficacy and toxicity for amphotericin B-loaded poly (ethylene oxide)-block-poly (beta benzyl L aspar-tate) micelles. J Controlled Release 1998; 56: 285–291.
   Google Scholar
• Gregoriadis G. Engineering liposomes for drug delivery: pro-gress and problems. Trends Biotechnol 1995; 13: 527–537.
   PubMed Web of Science ®Google Scholar
• Allen TM. Liposomal drug formulations. Rationale for devel-opment and what we can expect for the future. Drugs 1998; 56: 747–756.
   Google Scholar
• van Etten EW, ten Kate MT, Stearne LE, Bakker-Woudenberg IA. Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice. Antimicrob Agents Chemother 1995; 39: 1954–1958.
   Google Scholar
• van Etten EW, Snijders SV, van Vianen W, Bakker-Wouden-berg IA. Superior efficacy of liposomal amphotericin B with prolonged circulation in blood in the treatment of severe can-didiasis in leukopenic mice. Antimicrob Agents Chemother 1998; 42: 2431–2433.
   Google Scholar
• Van Etten EW, Steame-Cullen LE, ten Kate M, Bakker-Wou-denberg IA. Efficacy of liposomal amphotericin B with pro-longed circulation in blood in treatment of severe pulmonary aspergillosis in leukopenic rats. Antimicrob Agents Chemother 2000; 44: 540–545.
   PubMed Web of Science ®Google Scholar
• Otsubo T, Maruyama K, Maesaki S, et al. Long-circulating immunoliposomal amphotericin B against invasive pulmonary aspergillosis in mice. Antimicrob Agents Chemother 1998; 42: 40–44.
   PubMed Web of Science ®Google Scholar
• Heeres J, Backx LJJ, Van Cutsem J. Antimycotic azole. 7. Synthesis and antifungal properties of a series of novel triazol-3-ones. J Med Chem 1984; 27: 894–900.
   Google Scholar
• Richardson K, Branner KW, Marriott MS, Troke PF. Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagro-phytes. Antimicrob Agents Chemother 1985; 27: 832–835.
   PubMed Web of Science ®Google Scholar
• Verweij PE, de Pauw BE, Meis JF. Voriconazole (Pfizer Ltd). Curr Opinion Anti-infective Invest Drugs 1999; 1: 361–372.
   Google Scholar
• Espinel-Ingroff AV. Sch-56592 (Schering-Plough). Curr Opinion Anti-infective Invest Drugs 1999; 1: 377–384.
   Google Scholar
• Georgopapadakou NH. BMS-207147 (Eisai Co Ltd). Curr Opinion Anti-infective Invest Drugs 1999; 1: 373–376.
   Google Scholar
• Hector FR. Compounds active against cell walls of medically important fungi. Clin Microbiol Rev 1993; 6: 1–21.
   PubMedGoogle Scholar
• Denning DW. Echinocandins and pneumocandins — a new antifungal class with a novel mode of action. J Antimicrob Chemother 1997; 40: 611–614.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Coffman S. In vitro susceptibilities of clinical yeasts isolates to a new echinocandin derivative, LY 303366, and other antifungal agents. Antimicrob Agents Chemother 1997; 41: 763–766.
   Google Scholar
• Pfaller MA, Macro F, Messer SA, et al. In vitro activity of two echinocandin derivatives, LY 303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhi-zopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998; 30: 251–255.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Karlowsky JA, Harding GA, et al. In vitro activity of a new semisynthetic echinocandin, LY-303366, against sys-temic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob Agents Chemother 1997; 41: 863–865.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Karlowsky JA, Zelenitsky SA, et al. Susceptibility of Candida species isolated from the lower gastrointestinal tracts of high-risk patients to the new semisynthetic echinocan-din LY 303366 and other antifungal agents. Antimicrob Agents Chemother 1998; 42: 2446–2448.
   PubMed Web of Science ®Google Scholar
• Oakley KL, Moore CB, Denning DW. In vitro activity of the echinocandin antifungal agent LY 303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Anti-microb Agents Chemother 1998; 42: 2726–2730.
   Google Scholar
• Krishnarao TV, Galgiani JN. Comparison of the in vitro activ-ities of the echinocandin LY 303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother 1997; 41: 1957-1960.
   Google Scholar
• Karlowsky JA, Harding GA, Zelenitsky SA, et al. In vitro kill curves of a new semisynthetic echinocandin, LY-303366, against fluconazole-sensitiv e and -resistant Candida species. Anti-microb Agents Chemother 1997; 41: 2576–2578.
   PubMed Web of Science ®Google Scholar
• Current WL, Boylan CJ, Rabb PP. Anti-Pneumocystis activity of LY 303366 and other echinocandin B analogues. Program and Abstracts of the 33rd Interscience Conference on Antimicro-bial Agents and Chemotherapy, New Orleans, LA, October 17–20, 1993. Washington DC: American Society for Microbiol-ogy, 1993: 186.
   Google Scholar
• Zeckner D, Butler T, Boylan C, et al. In vitro evaluation of LY303366 against Candida species clinical isolates and evalua-tion of efficacy in a murine model of systemic candidiasis. Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17–20, 1995. Washington DC: American Society for Microbiology, 1995: 130.
   Google Scholar
• Rabb P, Zeckner D, Boylan C, et al. LY303366: Comparison of activity in murine models of Aspergillus fumigatus infection. Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, October 4–7, 1994. Washington DC: American Society for Microbiol-ogy, 1994: 252.
   Google Scholar
• Zeckner D, Butler T, Boylan C, et al. LY303366 activity against systemic aspergillosis and histoplasmosis in murine models. Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, October 17–20, 1993. Washington DC: American Society for Microbiology, 1993: 186.
   Google Scholar
• Zeckner D, Butler T, Boylan C, et al. LY303366 in a rat mucocutaneous vaginal candidiasis model. Program and Ab-stracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, October 4–7, 1994. Washington DC: American Society for Microbiology, 1994: 252.
   Google Scholar
• Zeckner D, Butler T, Boylan C, et al. LY303366 activity against in a murine systemic candidiasis model. Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, October 17–20, 1993. Wash-ington DC: American Society for Microbiology, 1993: 186.
   Google Scholar
• Petratiene R, Petraitis V, Groll A, et al. Antifungal efficacy, safety, and single dose plasma pharmacokinetics of LY303366, a novel echinocandin B, in experimental disseminated candidia-sis in persistently neutropenic rabbits. Antimicrob Agents Chemother 1999; 43: 2148–2155.
   PubMedGoogle Scholar
• Petraitis V, Petraitiene R, Candelario M, et al. Efficacy of LY303366, a semisynthetic echinocandin, against fluconazole-resistant esophageal candidiasis. Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 24–27, 1998. Wash-ington DC: American Society for Microbiology, 1998: Abstract J72.
   Google Scholar
• Petraitis V, Petratienes R, Groll A, et al. Antifungal efficacy, safety, and single dose plasma pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillo-sis in persistently neutropenic rabbits. Antimicrob Agents Chemother 1998; 42: 2898–2905.
   PubMed Web of Science ®Google Scholar
• Verweij PE, Oakley KL, Morrissey J, et al. Efficacy of LY 303366 against amphotericin B-susceptible and -resistant Asper-gillus fumigatus in a murine model of invasive aspergillosis. Antimicrob Agents Chemother 1998; 42: 873–878.
   PubMed Web of Science ®Google Scholar
• Groll AH, Mickiene D, Petraitiene R, et al. Noncompartmental single-dose plasma pharmacokinetics of the novel echinocandin LY303366 in rabbits. a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, Sep-tember 24–27, 1998. Washington DC: American Society for Microbiology, 1998: Abstract J59.
   Google Scholar
• Lukas R, Desante K, Hatcher B, et al. LY 303366 single dose pharmacokinetics and safety in healthy male volunteers. Pro-gram and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, September 15–18, 1996. Washington DC: American Society for Microbiology, 1996.
   Google Scholar
• Macro F, Pfaller MA, Messer SA, et al. Activity of MK-0991 (L-743-872), a new echinocandin, compared with those of LY 303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn Microbiol Infect Dis 1998; 3/ 33–37.
   Google Scholar
• Bartizal K, Gill CJ, Abruzzo GK, et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743-872). Antimicrob Agents Chemother 1997; 41: 2326–2332.
   PubMed Web of Science ®Google Scholar
• Vazquez JA, Lynch M, Boikov D, et al. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-suscep-tible and -resistant Candida species. Antimicrob Agents Chemother 1997; 41: 1612-1614.
   Google Scholar
• Franzot SP, Casadevall A. Pneumocandin L-743-872 enhances the activities of amphotericin B and fluconazole against Crypto-coccus neoformans in vitro. Antimicrob Agents Chemother 1997; 41: 331–336.
   PubMed Web of Science ®Google Scholar
• Graybill JR, Najvar LK, Luther MF, et al. Treatment of murine disseminated candidiasis with L-743872. Antimicrob Agents Chemother 1997; 41: 1775-1777.
   Google Scholar
• Abruzzo GK, Flattery AM, Gill CJ, et al. Evaluation of the echinocandin antifungal MK-0991 (L-743-872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1997; 41: 2333–2338.
   PubMed Web of Science ®Google Scholar
• Smith JG, Abruzzo CJ, Flattery AM, et al. Evaluation of pneumocandin L-743872 in neutropenic mouse models of dis-seminated candidiasis and aspergillosis against a murine sys-temic candidiasis model. Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemother-apy, New Orleans, LA, September 15–18, 1996. Washington DC: American Society for Microbiology, 1996: 141.
   Google Scholar
• Bartizal K, Smith JG, Gill CJ, et al. Preclinical efficacy of MK-0991 in pancytopenic mouse models of disseminated can-didiasis and aspergillosis against a murine systemic candidiasis model. Program and Abstracts of the 37th Interscience Confer-ence on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 28-October 1, 1997. Washington DC: American Society for Microbiology, 1997: 80.
   Google Scholar
• Powles MA, Liberator P, Anderson J, et al. Efficacy of MK-991 (L-743-872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob Agents Chemother 1998; 42: 1985-1989.
   Google Scholar
• Graybill JR, Najvar LK, Montalbo EM, et al. Treatment of histoplasmosis with MK-0991 (L-743,872). Antimicrob Agents Chemother 1998; 42: 151–153.
   PubMed Web of Science ®Google Scholar
• Hajdu R, Thompson R, Sundelof JG, et al. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother 1997; 41: 2339–2344.
   PubMed Web of Science ®Google Scholar
• Stone JA, Holland SD, Ju WD, et al. Single and multiple dose pharmacokinetics of the antifungal agent MK-0991 in man. Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 24–27, 1998. Washington DC: American Society for Microbiology, 1998: Abstract C51.
   Google Scholar
• Sable CA, Villanueva, Arathon E, et al. A randomized, double blind, multicenter trial of MK-0991 (L-743,872) vs ampho-tericin B (AmB) in the treatment of Candida esophagitis in adults. Abstracts of the 37th Interscience Conference on Antimi-crobial Agents and Chemotherapy, Toronto, Canada, September 28-October 1, 1997. Washington DC: American Society for Microbiology, 1997.
   Google Scholar
• Matsumoto S, Wakai Y, Maki K, et al. Efficacy of FK 463, a novel water-soluble echinocandin-like lipopeptide in murine models of disseminated candidiasis. Abstracts of the 38th Inter-science Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 24–27, 1998. Washington DC: American Society for Microbiology, 1998: Abstract 142.
   Google Scholar
• Wakai Y, Matsumoto S, Maki K, et al. Efficacy of FK 463, a novel water-soluble echinocandin-like lipopeptide in murine models of pulmonary aspergillosis. Abstracts of the 38th Inter-science Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 24–27, 1998. Washington DC: American Society for Microbiology, 1998: Abstract 143.
   Google Scholar
• Suzuki S, Terakawa M, Yokobayashi F, et al. Pharmacokinet-ics of FK 463, a novel water-soluble echinocandin-likelipopep- tide in animals. Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, Sep-tember 24–27, 1998. Washington DC: American Society for Microbiology, 1998: Abstract 144.
   Google Scholar
• Azuma J, Yamamoto I, Ogura M, et al. Phase I study of FK 463, new antifungal agent, in healthy adult male volunteers. Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 24–27, 1998. Washington DC: American Society for Microbiology, 1998: Abstract 146.
   Google Scholar
• Singleton P, Sainsbury D (eds). Dictionary of Microbiology & Molecular Biology. Chichester: John Wiley & Sons, 1993.
   Google Scholar
• Casadevall A, Pirofski LA. Host-pathogen interactions: redefin-ing the basic concepts of virulence and pathogenicity. Infect Immun 1999; 67: 3703–3713.
   PubMed Web of Science ®Google Scholar
• Perfect JR. Fungal virulence genes as targets for antifungal chemotherapy. Antimicrob Agents Chemother 1996; 40: 1577–1583.
   PubMedGoogle Scholar
• De Bernardis F, Muhlschlegel FA, Cassone A, Fonzi WA. The pH of the host niche controls gene expression in and virulence of Candida albicans. Infect Immun 1998; 66: 3317–3325.
   PubMed Web of Science ®Google Scholar
• Cruz MC, Del Poeta M, Wang P, et al. Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Crypt ococcus neofotmans via cyclophilin-dependent inhibition of calcineurin. Antimicrob Agents Chemother 2000; 44: 143–149.
   PubMed Web of Science ®Google Scholar
• Nussbaum G, Anandasabapathy S, Mukherjee J, Fan M, Casadevall A, Scharff MD. Molecular and idiotypic analyses of theantibody response to Crypt ococcus neoformans glu-curonoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune mice. Infect Immun 1999; 67: 4469–4476.
   PubMed Web of Science ®Google Scholar
• Groll AH, De Lucca AJ, Walsh TJ. Emerging targets for novel antifungal therapeutics. Trends Microbiol 1998; 6: 117–124.
   PubMed Web of Science ®Google Scholar
• Ghannoum MA. Potential role of phospholipases in virulence and fungal pathogenesis. Clin Microbiol Rev 2000; 13: 122–143.
   PubMed Web of Science ®Google Scholar
• Ghannoum MA. Extracellular phospholipases as universal viru-lence factor in pathogenic fungi. Nippon Ishinkin Gakkai Zasshi 1998; 39: 55–59.
   PubMedGoogle Scholar
• Leidich SD, Ibrahim AS, Fu Y, et al. Cloning and disruption of caPLB1, a phospholipase B gene involved in the pathogenicity of Candida albicans. J Biol Chem 1998; 273: 26078–26086.
   PubMed Web of Science ®Google Scholar
• Hanel H, Kirsch R, Schmidts HL, Kottmann H. New systemat-ically active antimycotics from the beta-blocker category. My-coses 1995; 38: 251–264.
   Google Scholar
• Mon K, Bausch K, Noonan J, Huguenel E, Tamburini P. Role of aspartic proteases in disseminated Candida albicans infection in mice. Infect Immun 1997; 65: 551–556.
   Google Scholar
• Korting HC, Schaller M, Eder G, Hamm G, Bohmer U, Hube B. Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activ-ities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients. Antimicrob Agents Chemother 1999; 43: 2038–2042.
   PubMed Web of Science ®Google Scholar
• Cassone A, De Bemardis F, Torosantucci A, Tacconelli E, Tumbarello M, Cauda R. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis 1999; 180: 448–453.
   PubMed Web of Science ®Google Scholar